AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease

NCT00606476 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

194

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: Bapineuzumab (AAB-001)

Sponsor

JANSSEN Alzheimer Immunotherapy Research & Development, LLC